---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-24-000035"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:36:28.968967+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q1: revenue up 5% to $141M, net loss widens to $59.9M; guidance reaffirmed

## Summary
- Revenue of $141.0M (+5% YoY); gross margin 66% vs 73% due to product mix shift to Xenium instruments.
- Net loss widened to $59.9M from $50.7M; operating loss $61.5M vs $52.0M.
- FY2024 revenue guidance maintained at $670M-$690M, representing 8-12% growth over FY2023.
- Shipped Visium HD for spatial discovery, GEM-X single cell technology, and Xenium cell segmentation products.
- Operating expenses up 3% to $154.4M; stock-based compensation declined to $36.1M.

## SEC filing metadata
- accession: 0001770787-24-000035
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/0001770787-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/txg-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-24-000035
- JSON: https://secwatch.observer/filing/0001770787-24-000035.json
- Plain text: https://secwatch.observer/filing/0001770787-24-000035.txt

## Key facts
- Earnings Releases
  10x Genomics, Inc. reported first quarter ended March 31, 2024 results: revenue $141.0 million, net income -$59.9 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $141.0 million
  - Net income: -$59.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue was $141.0 million for the first quarter of 2024, a 5% increase from $134.3 million for the corresponding prior year period. Gross margin was 66% for the first quarter of 2024, as compared to 73% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix driven by Xenium instruments. Operating expenses were $154.4 million for the first quarter of 2024, a 3% increase from $150.4 million for the corresponding prior year period. This increase was driven by higher legal expenses and costs for facilities and information technology partially offset by lower personnel expenses, including stock-based compensation. Operating loss was $61.5 million for the first quarter of 2024, as compared to $52.0 million for the corresponding prior year period. Operating loss includes $36.1 million of stock-based compensation for the first quarter of 2024, as compared to $42.1 million of stock-based compensation for the corresponding prior year per
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/0001770787-24-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.